Développement d'une thérapie pour l'Ataxie de Friedreich basée sur l'administration des protéines Tat-Frataxine et Pep-1-Frataxine
|Abstract:||Friedreich Ataxia is a rare and serious genetic disease involving neurodegeneration, cardiomyopathy and diabetes. It is caused by a drastic reduction of a mitochondrial protein called frataxin. The approach of the laboratory will be to develop on in vitro cells and in vivo mice models, a molecular therapy that will aim to provide the cells with a recombinant protein frataxin and if possible reduce the symptoms of the disease. To enable transduction of frataxin, we fused it to a protein transduction domain (Cell Penetrating Peptides, CPP), Tat or Pep-1. These peptides are well known for their ability to allow the penetration into the cells of the proteins to which they are fused through endocytosis vesicles, but also to be released from these vesicles to take part in the cell metabolism. Preliminary observations led us to conclude that the Tat-Frataxin and Pep-1-Frataxin protein enhance in vitro and in vivo the viability of cells deficient in endogenous frataxin.|
|Document Type:||Mémoire de maîtrise|
|Open Access Date:||23 April 2018|
|Collection:||Thèses et mémoires|
All documents in CorpusUL are protected by Copyright Act of Canada.